A Phase 1 and 2 Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of AZD8233 Following a Multiple Subcutaneous Dose Administration in Japanese Participants With Dyslipidemia
Latest Information Update: 06 Oct 2022
At a glance
- Drugs AZD-8233 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; Biomarker
- Acronyms HAYATE
- Sponsors AstraZeneca
- 03 Oct 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2022 Planned End Date changed from 30 Aug 2022 to 12 Sep 2022.